Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vaxcyte Inc (PCVX)

Vaxcyte Inc (PCVX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,825,318
  • Shares Outstanding, K 130,906
  • Annual Sales, $ 0 K
  • Annual Income, $ -463,930 K
  • EBIT $ -812 M
  • EBITDA $ -834 M
  • 60-Month Beta 1.28
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.00

Options Overview Details

View History
  • Implied Volatility 57.70% (-1.45%)
  • Historical Volatility 53.61%
  • IV Percentile 18%
  • IV Rank 18.95%
  • IV High 111.68% on 03/27/25
  • IV Low 45.09% on 01/15/25
  • Expected Move (DTE 5) 1.62 (3.63%)
  • Put/Call Vol Ratio 1.00
  • Today's Volume 4
  • Volume Avg (30-Day) 69
  • Put/Call OI Ratio 0.57
  • Today's Open Interest 8,938
  • Open Int (30-Day) 9,910
  • Expected Range 42.89 to 46.12

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.46
  • Number of Estimates 3
  • High Estimate -1.25
  • Low Estimate -1.66
  • Prior Year -1.02
  • Growth Rate Est. (year over year) -43.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
42.55 +4.58%
on 12/10/25
50.27 -11.48%
on 11/25/25
-1.60 (-3.47%)
since 11/12/25
3-Month
30.81 +44.43%
on 09/17/25
50.27 -11.48%
on 11/25/25
+12.33 (+38.33%)
since 09/12/25
52-Week
27.66 +60.88%
on 04/10/25
93.77 -52.54%
on 01/28/25
-43.37 (-49.36%)
since 12/12/24

Most Recent Stories

More News
Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Trial Design Finalized in Consultation and Alignment with U.S. Food and Drug Administration  Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines Through Head-to-Head...

PCVX : 44.50 (-0.20%)
These 3 Stocks Are Using Buybacks to Signal Market Confidence

Buybacks are getting a boost at three $20B to $200B firms. Does Trade Desk's repurchase authorization signal confidence, or is it too early to tell?

PCVX : 44.50 (-0.20%)
TTD : 36.65 (-1.00%)
TMO : 572.28 (-1.14%)
TPR : 123.21 (-0.23%)
AMZN : 226.19 (-1.78%)
Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study

Final Data from VAX-24 Infant Phase 2 Dose-Finding Study Consistent with Previously Reported Positive Interim Data; Provide Additional Evidence Supporting Higher VAX-31 Doses Being Evaluated in Ongoing...

PCVX : 44.50 (-0.20%)
BTIG Reaffirms Their Buy Rating on Vaxcyte (PCVX)

In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Vaxcyte, with a price target of $85.00. The company’s shares closed yesterday at $43.94.Elevate Your Investing Strategy:...

PCVX : 44.50 (-0.20%)
Bank of America Securities Keeps Their Buy Rating on Vaxcyte (PCVX)

In a report released today, Jason Gerberry from Bank of America Securities maintained a Buy rating on Vaxcyte, with a price target of $134.00. The company’s shares closed yesterday at $40.13.Elevate...

PCVX : 44.50 (-0.20%)
Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services

New Agreement with Thermo Fisher Scientific Expands Domestic Capacity to Support Future Commercial Manufacturing of Vaxcyte’s Broad-Spectrum Pneumococcal Conjugate Vaccine Candidates SAN CARLOS,...

PCVX : 44.50 (-0.20%)
Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose

VAX-31 Optimized Dose, with Majority of Serotypes Dosed at 4.4mcg and Balance at 3.3mcg, is Designed to Elicit Even Stronger Immune Responses in Infant Population to Protect Against Invasive Pneumococcal...

PCVX : 44.50 (-0.20%)
Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

PCVX : 44.50 (-0.20%)
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

PCVX : 44.50 (-0.20%)
2 ‘Strong Buy’ Growth Stocks That Could Gain More Than 340%

A volatile market presents the perfect opportunity to grab outstanding stocks at a bargain.

PCVX : 44.50 (-0.20%)
SEDG : 29.53 (-7.78%)
$SPX : 6,827.41 (-1.07%)
ENVX : 8.64 (-4.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Vaxcyte Inc.is a biopharmaceutical company develops vaccines for infectious diseases. It offers conjugate, pneumococcal conjugate and complex antigen-based vaccines. Vaxcyte Inc.is based in Foster City, California.

See More

Key Turning Points

3rd Resistance Point 46.51
2nd Resistance Point 45.72
1st Resistance Point 45.11
Last Price 44.50
1st Support Level 43.71
2nd Support Level 42.91
3rd Support Level 42.30

See More

52-Week High 93.77
Fibonacci 61.8% 68.52
Fibonacci 50% 60.71
Fibonacci 38.2% 52.91
Last Price 44.50
52-Week Low 27.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar